FASST banner Inventiva website FASST home page


Press Release

Inventiva Hits Clinical Milestone

April 2017: Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis (SSc)

  • FASST Phase 2b Clinical Trial on Track to Complete Enrollment in 2nd Half of 2017
  • Topline Results Anticipated in 2nd Half of 2018
Download the Press release

Annals of the Rheumatic diseases


The article « Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis », written by Prof. Yannick Allanore’s team, has been published in the Annals of the Rheumatic Diseases (Online First, 9 March 2016).
This article reports a study of the antifibrotic effects of IVA337, using a bleomycin-induced mouse model of dermal fibrosis. 
In conclusion, the findings of this study indicate that simultaneous activation of all three PPAR isoforms exerts a dampening effect on inflammation and fibrosis, making IVA337 a potentially effective therapeutic candidate in the treatment of fibrotic diseases including SSc.
Download the article for free

4th Systemic Sclerosis World Congress

Congress Communication

Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress in Lisbon, February 2016.
See more

contact us | © Inventiva 2016